| Sep 23 |
Elevai Labs announces pricing of $8 million public offering
|
| Sep 23 |
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
|
| Sep 10 |
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
|
| Sep 6 |
Elevai Labs files for 25M stock offering
|
| Sep 5 |
Elevai Labs Inc. (ELAB) National Hair Loss Aesthetics Slide Presentation
|
| Sep 3 |
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
|
| Aug 26 |
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
|
| Aug 26 |
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
|
| Aug 19 |
Elevai Labs Second Quarter 2024 Earnings: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023)
|
| Aug 19 |
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
|
